PRELUDE THERAPEUTICS INC (PRLD) Cash and securities
- Total cash · latest quarter (USD): Value $151.76M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $151.76M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $26.33M + $125.43M ≈ $151.76M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 26.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 125.43M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Cash and current securities | 151.76M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Quarter-end shares | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $151.76M | (m) | $26.33M | $125.43M | (m) |
| 2026-03-31 | $81.55M | (m) | $21.76M | $59.80M | (m) |
| 2025-12-31 | $103.21M | (m) | $35.26M | $67.96M | (m) |
| 2025-09-30 | $54.96M | (m) | $47.53M | $7.42M | (m) |
| 2025-06-30 | $73.22M | (m) | $25.75M | $47.46M | (m) |
| 2025-03-31 | $99.07M | (m) | $40.27M | $58.80M | (m) |
| 2024-12-31 | $133.61M | (m) | $12.47M | $121.14M | (m) |
| 2024-09-30 | $153.63M | (m) | $11.13M | $142.49M | (m) |
| 2024-06-30 | $179.84M | (m) | $27.83M | $152.02M | (m) |
| 2024-03-31 | $201.92M | (m) | $24.71M | $177.22M | (m) |
| 2023-12-31 | $232.94M | (m) | $25.29M | $207.64M | (m) |
| 2023-09-30 | $230.51M | (m) | $15.90M | $214.61M | (m) |
| 2023-06-30 | $254.99M | (m) | $26.45M | $228.54M | (m) |
| 2023-03-31 | $172.25M | (m) | $18.20M | $154.05M | (m) |
| 2022-12-31 | $201.73M | (m) | $30.61M | $171.12M | (m) |
| 2022-09-30 | $224.04M | (m) | $52.02M | $172.02M | (m) |
| 2022-06-30 | $246.31M | (m) | $50.71M | $195.60M | (m) |
| 2022-03-31 | $266.19M | (m) | $51.63M | $214.56M | (m) |
| 2021-12-31 | $291.23M | (m) | $31.83M | $259.40M | (m) |
| 2021-09-30 | $320.87M | (m) | $61.42M | $259.44M | (m) |
| 2021-06-30 | (m) | (m) | $343.12M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $362.99M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $218.31M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $234.79M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $18.88M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |